175 related articles for article (PubMed ID: 31545294)
21. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
22. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
23. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
24. The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.
Na YR; Kim JY; Song CH; Kim M; Do YT; Vo TTL; Choi E; Ha E; Seo JH; Shin SJ
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639155
[TBL] [Abstract][Full Text] [Related]
25. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
26. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
27. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
Ryan MR; Sohl CD; Luo B; Anderson KS
Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
[TBL] [Abstract][Full Text] [Related]
28. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor.
Lee SY; Na YJ; Jeong YA; Kim JL; Oh SC; Lee DH
Int J Biochem Cell Biol; 2018 Sep; 102():128-137. PubMed ID: 30044964
[TBL] [Abstract][Full Text] [Related]
30. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Fibroblast Growth Factor Receptor by AZD4547 Protects Against Inflammation in Septic Mice.
Huang Y; Wang F; Li H; Xu S; Xu W; Pan X; Hu Y; Mao L; Qian S; Pan J
Inflammation; 2019 Dec; 42(6):1957-1967. PubMed ID: 31321583
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
33. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
34. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
35. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
36. AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2022 Oct; 223():106132. PubMed ID: 35659529
[TBL] [Abstract][Full Text] [Related]
37. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract][Full Text] [Related]
38. Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
Hu C; Shang X; Zheng T; Hu X; Zhao Y
Biochem Biophys Res Commun; 2022 May; 604():165-171. PubMed ID: 35306249
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Kas SM; de Ruiter JR; Schipper K; Schut E; Bombardelli L; Wientjens E; Drenth AP; de Korte-Grimmerink R; Mahakena S; Phillips C; Smith PD; Klarenbeek S; van de Wetering K; Berns A; Wessels LFA; Jonkers J
Cancer Res; 2018 Oct; 78(19):5668-5679. PubMed ID: 30115694
[TBL] [Abstract][Full Text] [Related]
40. Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia.
Khandelwal AR; Rong X; Moore-Medlin T; Ekshyyan O; Abreo F; Gu X; Nathan CA
Cancer Prev Res (Phila); 2016 Apr; 9(4):296-304. PubMed ID: 26862088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]